New Cutting-Edge Report on Ophthalmology Therapeutics Market Published by MarketPublishers.com
10 Oct 2011 • by Natalie Aster
LONDON – The global ophthalmology market is expected to increase from last year’s USD 10.3 billion to USD 13.2 billion by 2017, growing at 3.6% CAGR. The introduction of new molecules, which are currently in the regulatory filing stage as well as in the later stages of development, will drive the market growth.
New report “Ophthalmology Therapeutics Market to 2017 - Protein Kinase Inhibitors and Prostaglandin H-Synthase Inhibitors to Drive Diabetic Retinopathy Market” prepared by GBI Research has been recently published by Market Publishers Ltd.
Report Details:
Title: Ophthalmology Therapeutics Market to 2017 - Protein Kinase Inhibitors and Prostaglandin H-Synthase Inhibitors to Drive Diabetic Retinopathy Market
Published: October, 2011
Pages: 156
Price: US$ 3,500.00
The report provides true insights into the current and future state of the world ophthalmology therapeutics market, detailing six therapeutic indications of ophthalmology - glaucoma, allergic conjunctivitis, dry eye syndrome, diabetic macular edema, diabetic retinopathy and wet age macular degeneration. It examines global ophthalmology treatment usage patterns for the aforementioned indications and gives insights into the ophthalmology therapeutics R&D product pipeline. Furthermore, drivers and restrains, competitive landscape, key M&A activities and licensing agreements are also featured.
Report Contents:
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 GLOBAL OPHTHALMOLOGY MARKET - INTRODUCTION
2.1 Overview
2.2 GBI Research Report Guidance
3 GLOBAL OPHTHALMOLOGY MARKET - MARKET CHARACTERIZATION
3.1 Introduction
3.2 Revenue Forecast for the Global Ophthalmology Market
3.2.1 Revenues
3.2.2 Annual Cost of Treatment (ACT)
3.3 Branded and Generic Market Share
3.4 Treatment Usage Patterns
3.4.1 Diseased Population
3.4.2 Treatment Seeking Population
3.4.3 Diagnosed Population
3.4.4 Prescription Population
4 GLOBAL OPHTHALMOLOGY MARKET - GEOGRAPHICAL LANDSCAPE
4.1 The US
4.1.1 Revenue
4.1.2 Annual Cost of Treatment
4.1.3 Treatment Usage Pattern
4.2 Top Five European Countries
4.2.1 Revenues of the Top Five European Countries
4.2.2 Annual Cost of Treatment
4.2.3 Treatment Usage Pattern
4.3 Japan
4.3.1 Revenues
4.3.2 Annual Cost of Treatment
4.3.3 Treatment Usage Pattern
5 GLOBAL OPHTHALMOLOGY MARKET - GLAUCOMA THERAPEUTICS MARKET
5.1 Introduction
5.2 Global Market Forecasts
5.3 Annual Cost of Treatment
5.4 Branded and Generic Market Share
5.5 Treatment Flow Algorithm
5.6 Treatment Usage Patterns
5.7 Market Forecasts for The US
5.8 Market Forecasts for the Top Five European Countries
5.9 Market Forecasts for Japan
5.10 Drivers of the Glaucoma Market
5.10.1 Increasing Prevalence of Eye Diseases
5.10.2 Improved Diagnosis of the Disease
5.11 Restraints for Glaucoma Market
5.11.1 Lower Awareness and Treatment Seeking Rates
5.11.2 Patent Expiry of Major Glaucoma Drugs such as Xalatan and Alphagan will Result in Negative Growth
6 GLOBAL OPHTHALMOLOGY MARKET - ALLERGIC CONJUNCTIVITIS
6.1 Introduction
6.1.1 Seasonal Allergic Conjunctivitis (SAC)
6.1.2 Perennial Allergic Conjunctivitis (PAC)
6.2 Market Forecasts
6.3 Annual Cost of Treatment
6.4 Branded and Generic Market Share
6.5 Treatment Flow Algorithm
6.6 Treatment Usage Patterns
6.7 Market Forecasts for the US
6.8 Market Forecasts for the Top Five European Countries
6.9 Market Forecasts for Japan
6.10 Drivers of Allergic Conjunctivitis Market
6.10.1 Increasing Awareness
6.11 Restraints for Allergic Conjunctivitis Market
6.11.1 Series of Patent Expires will Result in Slower Market Growth
7 GLOBAL OPHTHALMOLOGY MARKET - WET AGE MACULAR DEGENERATION
7.1 Introduction
7.2 Global Market Forecasts
7.3 Annual Cost of Treatment
7.4 Branded and Generic Market Share
7.5 Treatment Flow Algorithm
7.6 Treatment Usage Patterns
7.7 Market Forecasts for the US
7.8 Market Forecasts for the Top Five European Countries
7.9 Market Forecasts for Japan
7.10 Drivers of Macular Degeneration Market
7.10.1 Elderly Population to Drive Macular Degeneration Population
7.10.2 Active Research and Development Efforts will Drive Market
7.10.3 Improvements in Diagnostic Tools will Increase the Diagnosed Population
7.11 Restraints for Macular Degeneration Market
7.11.1 Extremely Poor Treatment Seeking Rates Especially for Wet Macular Degeneration will Result in Very Small Potential Customer Segment
7.11.2 Increasing Off Label Use of Cheaper Drugs will Impact Annual Cost of Therapy
8 GLOBAL OPHTHALMOLOGY MARKET - DIABETIC MACULAR EDEMA
8.1 Introduction
8.2 Global Market Forecasts
8.3 Annual Cost of Treatment
8.4 Branded and Generic Market Share
8.5 Treatment Flow Algorithm
8.6 Treatment Usage Patterns
8.7 Market Forecasts for The US
8.8 Market Forecasts for the Top Five European Countries
8.9 Market Forecasts for Japan
8.10 Drivers of the Diabetic Macular Edema Market
8.10.1 Increasing Prevalence of Conditions Such as Diabetes will Drive the Market
8.10.2 Improved Awareness will Drive Volumes
8.11 Restraints for Macular Edema Market
8.11.1 Availability of Effective Alternative Options Such as Laser Treatment
9 GLOBAL OPHTHALMOLOGY MARKET - DRY EYE SYNDROME
9.1 Introduction
9.2 Global Market Forecasts
9.3 Annual Cost of Treatment
9.4 Branded and Generic Market Share
9.5 Treatment Flow Algorithm
9.6 Treatment Usage Patterns
9.7 Market Forecasts for the US
9.8 Market Forecasts for the Top Five European Countries
9.9 Market Forecasts for Japan
9.10 Drivers for the DES Therapeutics Market
9.10.1 Increase in Prevalence
9.11 Barriers for the DES Therapeutics Market
9.11.1 Low Treatment Seeking Rate
9.11.2 Inadequate Treatment Options
10 GLOBAL OPHTHALMOLOGY MARKET - DIABETIC RETINOPATHY
10.1 Introduction
10.2 Global Market Forecasts
10.3 Annual Cost of Treatment
10.4 Branded and Generic Market Share
10.5 Treatment Flow Algorithm
10.6 Treatment Usage Patterns
10.7 Market Forecasts for The US
10.8 Market Forecasts for the Top Five European Countries
10.9 Market Forecasts for Japan
10.10 Drivers for the DR Therapeutics Market
10.10.1 Diabetic Population Growth
10.10.2 Advancement of Innovative Targeted Therapies
10.11 Barriers for the DR Therapeutics Market
10.11.1 Low Prescription Rates
10.11.2 Late Stage Diagnosis
11 GLOBAL OPHTHALMOLOGY MARKET - PIPELINE ANALYSIS
11.1 Introduction
11.2 Glaucoma - Research and Development Pipeline
11.2.1 Overview
11.2.2 Pipeline by Clinical Phases of Development
11.3 Diabetic Macular Edema - Research and Development Pipeline
11.3.1 Overview
11.3.2 Pipeline by Clinical Phases of Development
11.4 Wet Aged Macular Degeneration - Research and Development Pipeline
11.4.1 Overview
11.4.2 Pipeline by Clinical Phases of Development
11.5 Allergic Conjunctivitis - Research and Development Pipeline
11.5.1 Overview
11.5.2 Pipeline by Clinical Phases of Development
11.6 Dry Eye Syndrome - Research and Development Pipeline
11.6.1 Overview
11.6.2 Pipeline by Clinical Phases of Development
11.7 Diabetic Retinopathy - Research and Development Pipeline
11.7.1 Overview
11.7.2 Pipeline by Clinical Phases of Development
12 PROFILES OF PROMISING DRUGS IN OPHTHALMOLOGY THERAPEUTICS MARKET
12.1 Glaucoma
12.1.1 Tafluprost (Saflutan)
12.1.2 NCX-116 (Formerly PF-03187207)
12.2 Diabetic Macular Edema
12.2.1 Macugen (Pegaptanib Sodium)
12.2.2 Iluvien (Fluocinolone Acetonide)
12.2.3 iCo-007
12.3 Wet Age Macular Degeneration
12.3.1 VEGF Trap-Eye
12.4 Allergic Conjunctivitis
12.4.1 SCH 697243
12.4.2 Grass Pollen Allergoid
12.4.3 SAR 1118
12.5 Dry Eye Syndrome
12.5.1 Rebamipide (OPC-12759E)
12.5.2 CF101
12.5.3 Remura (Bromfenac)
12.5.4 Tasocitinib (CP-690550)
12.6 Diabetic Retinopathy
12.6.1 Lucentis (Ranibizumab)
12.6.2 Macugen (Pegaptanib Sodium)
12.6.3 Arxxant (Ruboxistaurin)
12.6.4 Vitreosolve
12.6.5 Nevanac (Nepafenac Ophthalmic)
13 GLOBAL OPHTHALMOLOGY MARKET - COMPETITIVE LANDSCAPE
13.1 Company Profiles for Ophthalmology
13.1.1 Pfizer
13.1.2 Allergan, Inc.
13.1.3 Alcon, Inc.
13.1.4 Novartis AG
13.1.5 Merck & Co Inc
13.1.6 Roche
14 GLOBAL OPHTHALMOLOGY MARKET - STRATEGIC CONSOLIDATIONS
14.1 Mergers and Acquisitions
14.1.1 Overview
14.1.2 Major Mergers and Acquisitions Deals
14.1.3 Segmentation by Geography
14.1.4 Segmentation by Deal Value
14.2 Co-development Deals
14.2.1 Major Co-development Deals
14.2.2 Segmentation by Geography
14.3 Licensing Deals
14.3.1 Major Licensing Deals
14.3.2 Segmentation by Geography
14.3.3 Segmentation by Value
15 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - APPENDIX
15.1 Market Definitions
15.2 Abbreviations
15.3 Research Methodology
15.3.1 Coverage
15.3.2 Secondary Research
15.3.3 Primary Research
15.4 Therapeutic Landscape
15.4.2 Market Size by Geography
15.5 Geographical Landscape
15.6 Pipeline Analysis
15.7 Competitive Landscape
15.7.1 Expert Panel Validation
15.8 Contact Us
15.9 Disclaimer
15.10 Sources
LIST OF TABLES
LIST OF FIGURES
COMPANIES MENTIONED
Pfizer
Allergan, Inc.
Alcon, Inc.
Novartis AG
Merck & Co Inc
Roche
Reports Examining other Medicine, Pharmaceuticals & Biotechnology Markets are also Available:
- Clinical Trial Recruitment in Dermatology - Most Trials Focus on Atopic Dermatitis While Acne Vulgaris Has Highest Patient Numbers
- Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly
- Contraceptives Market to 2017 - Hormonal Contraceptives and Strong Pipeline to Drive the Growth in Future
- HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries
- Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value
More new reports by the publisher can be found at GBI Research page.
CONTACTS
The Market Publishers, Ltd.
Mrs. Tanya Rezler
Tel: +44 208 123 2220
Fax: +44 207 900 3970